138 related articles for article (PubMed ID: 27425812)
1. Bendamustine combined regimen for Hodgkin's lymphoma.
Venkatesan P
Lancet Oncol; 2016 Aug; 17(8):e326. PubMed ID: 27425812
[No Abstract] [Full Text] [Related]
2. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
3. Using PET-CT to tailor treatment for Hodgkin's lymphoma.
Tanday S
Lancet Oncol; 2016 Aug; 17(8):e322. PubMed ID: 27345638
[No Abstract] [Full Text] [Related]
4. Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Pellegrini C; Maglie R; Argnani L; Pileri S; Zinzani PL
Hematol Oncol; 2016 Mar; 34(1):49-51. PubMed ID: 25243375
[No Abstract] [Full Text] [Related]
5. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Kalac M; Lue JK; Lichtenstein E; Turenne I; Rojas C; Amengual JE; Sawas A; Deng C; Mapara MY; Connors JM; Kuruvilla J; O'Connor OA
Br J Haematol; 2018 Mar; 180(5):757-760. PubMed ID: 27984643
[No Abstract] [Full Text] [Related]
6. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
[No Abstract] [Full Text] [Related]
7. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
8. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
Elsoueidi R; Mulat A; Mourad H
J Oncol Pharm Pract; 2014 Aug; 20(4):309-11. PubMed ID: 24847047
[TBL] [Abstract][Full Text] [Related]
10. Early bone marrow transplantation in Hodgkin's disease.
Armitage JO
Ann Oncol; 1994; 5 Suppl 2():161-3. PubMed ID: 8204515
[TBL] [Abstract][Full Text] [Related]
11. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma.
Hohaus S; Di Febo A; Storti S; Teofili L; Voso MT; Leone G
Haematologica; 2004 Jun; 89(6):751-2. PubMed ID: 15194545
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
[TBL] [Abstract][Full Text] [Related]
14. Probability of cure in elderly Hodgkin's disease patients.
Levis A; Depaoli L; Urgesi A; Bertini M; Orsucci L; Vitolo U; Buchi G; Gallamini A; Gavarotti P; Novarino A; Rota Scalabrini D; Mazza U; Pileri A; Sannazzari GL; Resegotti L
Haematologica; 1994; 79(1):46-54. PubMed ID: 15378948
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
16. Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies.
Diehl V; Fuchs M
Ann Oncol; 2007 Jul; 18 Suppl 9():ix71-9. PubMed ID: 17631599
[No Abstract] [Full Text] [Related]
17. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
19. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
20. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
